TUS+VEN+AZA triplet achieves Cycle 1 complete remission (CR) in TP53-mutated/CK AMLTUS+VEN+AZA triplet achieves Cycle 1 complete remissions in FLT3-wildtype AML…
Proceeds expected to fund the start of the ALG-000184 Phase 2 clinical study Funding expected to extend cash runway into…
SOUTH SAN FRANCISCO, Calif., Feb. 12, 2025 (GLOBE NEWSWIRE) -- Standard BioTools Inc. (NASDAQ: LAB) today announced that it will…
LONDON and NEW YORK, Feb. 12, 2025 (GLOBE NEWSWIRE) -- OKYO Pharma Limited (NASDAQ: OKYO), a clinical-stage biopharmaceutical company developing…
Vancouver, British Columbia and Rehovot, Israel--(Newsfile Corp. - February 12, 2025) - BioHarvest Sciences Inc. (NASDAQ: BHST) (CSE: BHSC) (FSE:…
Halifax, Nova Scotia--(Newsfile Corp. - February 12, 2025) - Sona Nanotech Inc. (CSE: SONA) (OTCQB: SNANF) (the "Company", "Sona") is…
Toronto, Ontario--(Newsfile Corp. - February 12, 2025) - Glow Lifetech Corp. (CSE: GLOW) (OTC Pink: GLWLF) (FSE: 9DO) ("Glow" or…
Positive Recommendation by DSMB to Continue Enrollment of Phase 3 SHIELD II Trial of D-PLEX₁₀₀ to 800 Patients SHIELD II…
- Data Generated to Date Support Potential for Aclaris’ ATI-2138 to Impact Several Human Inflammatory Diseases - WAYNE, Pa., Feb.…
Bioxodes raises €2.7 million from existing investors in Series A extensionInterim data from BIRCH intracerebral hemorrhage (ICH) Phase 2a trial…